Lamotrigine is indicated for the treatment of partial and generalised seizures in adults and increasingly, in children. It may also have a role in the treatment of conditions such as Parkinson's disease. Adverse reactions are relativel minor, for example: (nausea, headache and dizziness). A typical dosage for Lamotrigine is 200-400 mg. bd; a therapeutic range of 1.0-4.0mg/L has been proposed by Wellcome. The half-life of the drug is around 24hours; although this is affected by concomitant therapy. Lamotrigine is known to delay the metabolism of carbamzepine and may also interact with other drugs. There is no therapeutic range for Lamotrigine and the tentative therapeutic range of 1-4 mg/L is suggested but this may be of limited value.
Trough specimen taken pre-dose or minimum 6hrs post-dose
Therapeutic range (epilepsy): 1 - 4 mg/L
Maximum drug efficacy (bipolar disorder): 3 - 14 mg/L
Copyright heftpathology 2013, 2014, 2015, 2016, 2017, 2018
HTA licence number is 12366
Protection of Personal Information – Laboratory Medicine comply with the Trust Data Protection Policy and have procedures in place to allow the Directorate and it’s employees to comply with the Data Protection Act 1998 and associated best practice and guidance.
The Trust Laboratories at Heartlands Hospital, Good Hope Hospital and Solihull Hospital were awarded UKAS (United Kingdom Accreditation Service) accreditation to the internationally recognised ISO 15189 standard in May 2015. For a list of accredited tests and other information please visit the test database http://www.heftpathology.com/frontpage/test-database.html.
Tests not appearing on this scope are either under consideration or in the process of accreditation and so currently remain outside of our scope of accreditation. However, these tests have been validated to the same high standard as accredited tests and are performed by the same trained and competent staff.
For further information contact Louise Fallon, Quality Manager, 0121 424 1235